Imatinib
Unspecified Adult Solid Tumor
University of California, San FranciscoSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Unspecified Adult Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
D-thioctic acid US Department of Veterans Affairs | Phase 2/3 | B |
Irinotecan Jonsson Comprehensive Cancer Center | Phase 1 | CCC |
Cediranib Rutgers, The State University of New Jersey | Phase 1 | CCC |
Sorafenib Virginia Commonwealth University | Phase 1 | CC |
Talzenna Jonsson Comprehensive Cancer Center | Phase 1 | CC |
(+)-VINCRISTINE University of California, San Francisco | Phase 1 | CC |
Cyclophosphamide University of California, San Francisco | Phase 1 | CC |
Dordaviprone Rutgers, The State University of New Jersey | Phase 1 | CC |
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →